PT - JOURNAL ARTICLE AU - Tamar Sofer AU - Jiwon Lee AU - Nuzulul Kurniansyah AU - Deepti Jain AU - Cecelia A. Laurie AU - Stephanie M. Gogarten AU - Matthew P. Conomos AU - Ben Heavner AU - Yao Hu AU - Charles Kooperberg AU - Jeffrey Haessler AU - Ramachandran S. Vasan AU - L. Adrienne Cupples AU - Brandon J. Coombes AU - Amanda Seyerle AU - Sina A. Gharib AU - Han Chen AU - Jeffrey R. O’Connell AU - Man Zhang AU - Daniel Gottlieb AU - Bruce M. Psaty AU - W.T. Longstreth, Jr. AU - Jerome I. Rotter AU - Kent D. Taylor AU - Stephen S. Rich AU - Xiuqing Guo AU - Eric Boerwinkle AU - Alanna C. Morrison AU - James S. Pankow AU - Andrew D. Johnson AU - Nathan Pankratz AU - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium AU - Alex P. Reiner AU - Susan Redline AU - Nicholas L. Smith AU - Kenneth M. Rice AU - Elizabeth D. Schifano TI - BinomiRare: A carriers-only test for association of rare genetic variants with a binary outcome for mixed models and any case-control proportion AID - 10.1101/2021.01.08.21249450 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.08.21249450 4099 - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249450.short 4100 - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249450.full AB - Whole genome and exome sequencing studies have become increasingly available and are being used to identify rare genetic variants associated with health and disease outcomes. Investigators routinely use mixed models to account for genetic relatedness or other clustering variables (e.g. family or household) when testing genetic associations. However, no existing tests of the association of a rare variant association with a binary outcome in the presence of correlated data controls the Type 1 error where there are (1) few carriers of the rare allele, (2) a small proportion of cases relative to controls, and (3) covariates to adjust for. Here, we address all three issues in developing the carriers-only test framework for testing rare variant association with a binary trait. In this framework, we estimate outcome probabilities under the null hypothesis, and then use them, within the carriers, to test variant associations. We extend the BinomiRare test, which was previously proposed for independent observations, and develop the Conway-Maxwell-Poisson (CMP) test, and study their properties in simulations. We show that the BinomiRare test always controls the type 1 error, while the CMP test sometimes does not. We then use the BinomiRare test to test the association of rare genetic variants in target genes with small vessel disease stroke, short sleep, and venous thromboembolism, in whole-genome sequence data from the Trans-Omics for Precision Medicine program.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Heart Lung and Blood Institute grant R35HL135818. Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). See Supplementary Note 2 for sequencing center support information. Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sample-identity QC, and general study coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis manuscript used genome-sequencing data from TOPMed, and phenotypes from TOPMed participating studies. These data are available by application to dbGaP using study-specific accessions (phs numbers). WGS for "NHLBI TOPMed: Genetics of Cardiometabolic Health in the Amish" (phs000956) was performed at the Broad Institute of MIT and Harvard (3R01HL121007-01S1). WGS for "NHLBI TOPMed: Cleveland Family Study - WGS Collaboration" (phs000954) was performed at the University of Washington Northwest Genomics Center (3R01HL098433-05S1, HHSN268201600032I). WGS for "NHLBI TOPMed: Cardiovascular Health Study" (phs001368.v2.p2) was performed at Baylor Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C, HHSN268201600033I). WGS for "NHLBI TOPMed: Framingham Heart Study" (phs000974) was performed at the Broad Institute of MIT and Harvard (3R01HL092577-06S1, 3U54HG003067-12S2). WGS for "NHLBI TOPMed: Heart and Vascular Health Study (HVH)" (phs000993.v4.p2) was performed at Baylor Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C). WGS for "NHLBI TOPMed: Jackson Heart Study" (phs000964) was performed at the University of Washington Northwest Genomics Center (HHSN268201100037C). WGS for "NHLBI TOPMed: Multi Ethnic Study of Atherosclerosis" (phs001416) was performed at the Broad Institute of MIT and Harvard (3R01HL092577-06S1, 3U54HG003067-12S2). WGS for "NHLBI TOPMed: Whole Genome Sequencing of Venous Thromboembolism (WGS or VTE)" (phs001402.v2.p1) was performed at Baylor Genome Sequencing Center (3U54HG003273-12S2, HHSN268201500015C). WGS for "NHLBI TOPMed: Women's Health Initiative (WHI)" (phs001237.v2.p1) was performed at the Broad Institute of MIT and Harvard (HHSN268201500014C).